https://orcid.org/0000-0001-8765-9649
References
- Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626.
- Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
- Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410.
- Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020;188(3):394–403.
- Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenström macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol. 2018;93(4):511–517.
- Castillo J, Xu L, Gustine JN, et al. CXCR4 mutations subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinemia treated with ibrutinib. Br J Haematol. 2019;187(3):356–363.
- Liebowitz D. A phase 1 multidose study to evaluate the safety and tolerability of XmAb®13676 in patients with CD20-expressing hematologic malignancies. Unpublished investigator brochure, Version 8, September 22, 2020.
- Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176.
- Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646.
- Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in waldenström macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–1588.
- Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom’s macroglobulinemia. Haematologica. 2013;98(4):649–654.
- Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120–4131.
- Banwait R, Aljawai Y, Cappuccio J, et al. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015;90(2):100–104.
- Cooper SL, Brown PA. Resistance to bispecific T-Cell engagers and bispecific antibodies. In: Xavier A, Cairo M, editors. Resistance to targeted therapies in lymphomas. Resistance to targeted anti-cancer therapeutics. Vol. 21. Cham: Springer. 2019. p. 181–192.